{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:14:35Z","timestamp":1789748075157,"version":"4.0.1"},"reference-count":61,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DDDT"],"DOI":"10.2147\/dddt.s334727","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T16:30:28Z","timestamp":1645029028000},"page":"363-374","source":"Crossref","is-referenced-by-count":58,"title":["Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata"],"prefix":"10.2147","volume":"Volume 16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-8880","authenticated-orcid":true,"given":"Hassiel Aurelio","family":"Ram\u00edrez-Mar\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Tosti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.2147\/CCID.S53985","volume":"8","author":"Villasante Fricke","year":"2015","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"17011","DOI":"10.1038\/nrdp.2017.11","volume":"3","author":"Pratt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1001\/archderm.1992.01680150136027","volume":"128","author":"Safavi","year":"1992","journal-title":"Arch Dermatol"},{"key":"ref4","unstructured":"National Alopecia Areata Foundation. What you need to know about alopecia areata; 2021. Available from: https:\/\/www.naaf.org\/alopecia-areata. Accessed November 5, 2021."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1111\/j.1468-3083","volume":"20","author":"Goh","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"180","DOI":"10.2340\/0001555549180188","volume":"49","author":"Gip","year":"1969","journal-title":"Acta Derm Venereol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2006.05.008","volume":"55","author":"Tosti","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1365-2230.1989.tb02604.x","volume":"14","author":"De Waard-van der Spek","year":"1989","journal-title":"Clin Exp Dermatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.4065\/70.7.628","volume":"70","author":"Safavi","year":"1995","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"72","DOI":"10.12788\/j.sder.2015.0160","volume":"34","author":"Hordinsky","year":"2015","journal-title":"Semin Cutan Med Surg"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2008.03.002","volume":"28","author":"O\u2019Shea","year":"2008","journal-title":"Immunity"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nri2580","volume":"9","author":"Rochman","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1038\/nm.3645","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.5114\/ada.2020.102103","volume":"37","author":"El Aziz Ragab","year":"2020","journal-title":"Postepy Dermatol Alergol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/jid.2010.260","volume":"130","author":"Gilhar","year":"2010","journal-title":"J Invest Dermatol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"114760","DOI":"10.1016\/j.bcp.2021.114760","volume":"193","author":"Tzeng","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"ref20","unstructured":"United States Food and Drug Administration. Coronavirus (COVID-19) Update: FDA authorizes drug combination for treatment of COVID-19. FDA news release; 2020. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19. Accessed November 3, 2021."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1016\/j.jid.2018.01.032","volume":"138","author":"Jabbari","year":"2018","journal-title":"J Invest Dermatol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"Kennedy Crispin","year":"2016","journal-title":"JCI Insight"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaad.2016.09.006","volume":"76","author":"Craiglow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Casella J. AAD 2019; S034, Abstract 11291.","DOI":"10.5465\/AMBPP.2019.11291abstract"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jaad.2018.08.040","volume":"80","author":"Liu","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1021\/jm401490p","volume":"57","author":"Clark","year":"2014","journal-title":"J Med Chem"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/nrd.2017.201","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1093\/rheumatology\/key339","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e142205","DOI":"10.1172\/jci.insight.142205","volume":"6","author":"Dai","year":"2021","journal-title":"JCI Insight"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/377065a0","volume":"377","author":"Macchi","year":"1995","journal-title":"Nature"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15605","author":"Jo","year":"2021","journal-title":"Int J Dermatol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1146\/annurev.immunol.22.012703.104743","volume":"23","author":"Berg","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nri1591","volume":"5","author":"Schwartzberg","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"a002287","DOI":"10.1101\/cshperspect.a002287","volume":"2","author":"Andreotti","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.molimm.2010.12.007","volume":"48","author":"Kurosaki","year":"2011","journal-title":"Mol Immunol"},{"key":"ref40","unstructured":"Selleckchek.com. Ritlecitinib (PF-06651600); 2021. Available from: https:\/\/www.selleckchem.com\/products\/pf-06651600.html. Accessed November 3, 2021."},{"key":"ref41","unstructured":"NCIthesaurus. Ritlecitinib; 2021. Available from: https:\/\/ncithesaurus.nci.nih.gov\/ncitbrowser\/pages\/concept_details.jsf?dictionary=NCI_Thesaurus&version=21.10d&code=C161783\u2284ncit&type=properties&key=null&b=1&n=0&vse=null. Accessed November 3, 2021."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1021\/acschembio.6b00677","volume":"11","author":"Telliez","year":"2016","journal-title":"ACS Chem Biol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"ref44","unstructured":"ClinicalTrials.gov. Study to evaluate the efficacy and safety profile of PF-06651600 and PF-06700841 in subjects with alopecia areata; 2020. Availabe from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02974868. Accessed November 5, 2021."},{"key":"ref45","unstructured":"Peeva E, Banerjee A. Oral Janus kinase inhibitors PF-06700841 and PF-06651600 provide clinically evident therapeutic effect at 4 and 6 weeks in patients with alopecia areata and greater efficacy over 24 weeks in patients with a shorter duration of their current alopecia episo. American Academy of Dermatology Annual Meeting; 2019; Washington, DC, USA."},{"key":"ref46","unstructured":"ClinicalTrials.gov. Placebo-controlled safety study of ritlecitinib (PF-06651600) in adults with alopecia areata (Allegro2a); 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04517864. Accessed November 2, 2021."},{"key":"ref47","unstructured":"ClinicalTrials.gov. PF-06651600 for the treatment of alopecia areata (ALLEGRO-2b\/3); 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03732807?id=NCT03732807&draw=2&rank=1. Accessed November 2, 2021."},{"key":"ref48","unstructured":"Pfizer. Pfizer announces positive top-line results from Phase 2b\/3 trial of ritlecitinib in alopecia areata. Press release; 2021. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-announces-positive-top-line-results-phase-2b3-trial. Accessed November 11, 2021."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1016\/j.jaad.2003.09.032","volume":"51","author":"Olsen","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"ref50","unstructured":"ClinicalTrials.gov. Long-term PF-06651600 for the treatment of alopecia areata (ALLEGRO-LT); 2021. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04006457. Accessed November 2, 2021."},{"key":"ref51","unstructured":"Peeva E, Banerjee A, Guttman-Yassky E, et al. Safety and Efficacy of the Oral JAK3\/TEC Inhibitor PF-06651600 and the Oral TYK2\/JAK1 Inhibitor PF-06700841 in a withdrawal\/re-treatment extension study in patients with alopecia areata. Presented at the 28th Congress of the European Academy of Dermatology and Venereology."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1759720X20930116","DOI":"10.1177\/1759720X209301","volume":"12","author":"Evangelatos","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1759720X20936059","DOI":"10.1177\/1759720X20936059","volume":"12","author":"Sunzini","year":"2020","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"i34","DOI":"10.1093\/rheumatology\/key287","volume":"58","author":"Harigai","year":"2019","journal-title":"Rheumatology"},{"key":"ref56","unstructured":"Khan S. How do jak inhibitors (DMARDS) work?; 2021. Available from: https:\/\/www.rxlist.com\/how_do_jak_inhibitors_dmards_work\/drug-class.htm. Accessed November 3, 2021."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12865-020-00365-w","volume":"21","author":"Fujita","year":"2020","journal-title":"BMC Immunol"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"i43","DOI":"10.1093\/rheumatology\/key276","volume":"58","author":"Fragoulis","year":"2019","journal-title":"Rheumatology"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","volume":"37","author":"Rajasimhan","year":"2020","journal-title":"Drugs Aging"},{"key":"ref60","unstructured":"Administration USF and D. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions; 2021."},{"key":"ref61","unstructured":"Peeva E, Craiglow B, Banerjee A, et al. A Phase 2a randomized, placebo-controlled study to evaluate efficacy and safety of janusfi kinase inhibitors PF-06651600 and PF-06700841 in alopecia areata: 24-week results. Presented at the 27th Congress of the Europea."}],"container-title":["Drug Design, Development and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=78377","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=78377","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T19:33:26Z","timestamp":1726688006000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/evaluating-the-therapeutic-potential-of-ritlecitinib-for-the-treatment-peer-reviewed-fulltext-article-DDDT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":61,"URL":"https:\/\/doi.org\/10.2147\/dddt.s334727","relation":{},"ISSN":["1177-8881"],"issn-type":[{"value":"1177-8881","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}